Compare Mesoblast Limited (MESO) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Health Care Select Sector SPDR Fund — how do they compare? Mesoblast Limited trades at $16.87 (market cap $2.21B), while Health Care Select Sector SPDR Fund trades at $168.41. The key difference: Health Care Select Sector SPDR Fund is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| MESO | XLV | |
|---|---|---|
Market Cap | $2.21B | — |
Sector | Technology | — |
52-Week High | $20.96 | $168.44 |
52-Week Low | $12.88 | $131.16 |
Enterprise Value | $2.21B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.9, up 1.32% on the day, with a bullish technical signal from moving averages. The company reported Ryoncil net revenues of $36 million for the quarter ended June 30, 2026, and achieved its target of 300 patients in a Phase 3 trial for chronic low back pain. Despite strong revenue growth from its commercial launch, fundamentals show a net income margin of -144.33% and negative EBITDA of $80.06 million for 2025, reflecting significant losses amid expansion.
The outlook hinges on commercial execution and regulatory progress, with analyst consensus leaning buy (45% buy ratings). Key risks include high cash burn, dependence on pipeline success, and competitive pressures. Upside potential exists if revenue growth accelerates and losses narrow, but investors face volatility from clinical trial outcomes and funding needs.
XLV, the Health Care Select Sector SPDR ETF, trades at $167.1, down 0.8% on the day. The technical outlook is bullish based on moving averages, though short-term oscillators signal overbought conditions. Recent news highlights the ETF's defensive appeal amid economic uncertainty and its competitive edge with a low 0.08% expense ratio. Strong healthcare earnings and investor inflows into defensive sectors support positive momentum.
The outlook for XLV is positive, driven by defensive sector demand and solid underlying holdings. Key opportunities include cost efficiency and diversification across 60 healthcare stocks. Risks involve sector-specific pressures like regulatory changes and liquidity challenges. Analyst sentiment remains favorable, with the ETF well-positioned for steady growth in a volatile market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Health Care Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →
